Animal Health, Nutrition and Technology Innovation Europe 2023

Shaping the Future of the Animal Health Industry by Showcasing Innovations in Prediction, Prevention and Treatment

See highlights from 2022
London, UK
6-8 March, 2023

Why Attend?

Animal Health, Nutrition and Technology Innovation Europe is the sector’s premier innovation summit, showcasing the most exciting emerging companies and connecting them with investors and strategic partners.

Our mission is to engage all key participants in the value chain so we can address the full scope of how animal health impacts pet owners, veterinarians, and farmers today.


We would be delighted for you to join us as we address the challenges and opportunities for innovation in our ever-evolving industry.

650+
Attendees
1500+
1-to-1 Meetings
150+
Start-ups
20
Emerging Companies Presenting
20+
Private Meetings per person

Innovation Showcase

The Innovation Showcase is back for 2023!

The showcase is a unique opportunity for emerging companies with amazing technology to present in front of the industry’s most influential figures and investors. 

Applications have now closed. Finalists will be announced soon!

2023 Speakers

 

Kristin Peck

Chief Executive Officer
Zoetis

Kristin Peck

Chief Executive Officer
Zoetis

Kristin Peck

Chief Executive Officer
Zoetis
 

Jeff Simmons

Chief Executive Officer
Elanco

Jeff Simmons

Chief Executive Officer
Elanco

Jeff Simmons

Chief Executive Officer
Elanco
 

Robert Kelly

Senior Vice President, Commercial Leader for EURAM Region
MSD

Robert Kelly

Senior Vice President, Commercial Leader for EURAM Region
MSD

Robert Kelly

Senior Vice President, Commercial Leader for EURAM Region
MSD
 

Glenn David

EVP and Group President, International Operations, Aquaculture, BioDevices and Pet Insurance
Zoetis Inc.

Glenn David

EVP and Group President, International Operations, Aquaculture, BioDevices and Pet Insurance
Zoetis Inc.

Glenn David

EVP and Group President, International Operations, Aquaculture, BioDevices and Pet Insurance
Zoetis Inc.
 

Laetitia Cicchelero

Cross-Health Coordinator
Ghent University

Laetitia Cicchelero

Cross-Health Coordinator
Ghent University

Laetitia Cicchelero

Cross-Health Coordinator
Ghent University
 

Matt Dobbs

Global Chief Medical Officer
Destination Pet

Matt Dobbs

Global Chief Medical Officer
Destination Pet

Matt Dobbs

Global Chief Medical Officer
Destination Pet
 

Simon Doherty

Associate Fellow
Queen’s University Belfast

Simon Doherty

Associate Fellow
Queen’s University Belfast

Simon Doherty

Associate Fellow
Queen’s University Belfast
 

Vinicius Chiappetta

Global Commercial Director – Cargill Digital Solutions
Cargill

Vinicius Chiappetta

Global Commercial Director – Cargill Digital Solutions
Cargill

Vinicius Chiappetta

Global Commercial Director – Cargill Digital Solutions
Cargill
 

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd
 

Carel du Marchie Sarvaas

Executive Director
HealthforAnimals Global Animal Health Association

Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

Carel du Marchie Sarvaas

Executive Director
HealthforAnimals Global Animal Health Association

Carel du Marchie Sarvaas

Executive Director
HealthforAnimals Global Animal Health Association

Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins University

 

Jamie Brannan

EVP and President International Operations and Aquaculture
Zoetis

Jamie Brannan

EVP and President International Operations and Aquaculture
Zoetis

Jamie Brannan

EVP and President International Operations and Aquaculture
Zoetis
 

Mariama Boumanjal

Start-up Partner Manager
Google

Mariama Boumanjal

Start-up Partner Manager
Google

Mariama Boumanjal

Start-up Partner Manager
Google
 

Kathy Turner

Senior Vice President & Global Chief Marketing Officer
IDEXX

Kathy Turner

Senior Vice President & Global Chief Marketing Officer
IDEXX

Kathy Turner

Senior Vice President & Global Chief Marketing Officer
IDEXX
 

Julia Stephanus

Partner
Borealis Ventures

Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

Julia Stephanus

Partner
Borealis Ventures

Julia Stephanus

Partner
Borealis Ventures

Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

 

Ellen de Brabander

Executive Vice President R&D and Innovation
Elanco

Ellen de Brabander

Executive Vice President R&D and Innovation
Elanco

Ellen de Brabander

Executive Vice President R&D and Innovation
Elanco
 

Sven Arnouts

Business Development
Ghent University

Sven Arnouts

Business Development
Ghent University

Sven Arnouts

Business Development
Ghent University
 

Justine Conway

Global Head of Business Development
Elanco

Justine Conway

Global Head of Business Development
Elanco

Justine Conway

Global Head of Business Development
Elanco
 

Dr. Lawrence Brown

Senior Technical and Account Manager
Anpario

Dr Lawrence Brown is a Sector Specialist (Animal Sciences & Aquaculture) for the Department for International Trade. His main focus is on inward investment into the UK but also assists with trade. Lawrence is a qualified veterinary surgeon and consultant, working with private and public sector clients through his consultancy company LJB Veterinary Services Ltd. He is an elected member of the British Veterinary Association's (BVA) Scottish Council and is studying for an Executive MBA at the University of Edinburgh.

Dr. Lawrence Brown

Senior Technical and Account Manager
Anpario

Dr. Lawrence Brown

Senior Technical and Account Manager
Anpario

Dr Lawrence Brown is a Sector Specialist (Animal Sciences & Aquaculture) for the Department for International Trade. His main focus is on inward investment into the UK but also assists with trade. Lawrence is a qualified veterinary surgeon and consultant, working with private and public sector clients through his consultancy company LJB Veterinary Services Ltd. He is an elected member of the British Veterinary Association's (BVA) Scottish Council and is studying for an Executive MBA at the University of Edinburgh.

 

Ivan Farneti

Founding Partner
Five Season Ventures

Ivan has been an active venture capital investor for the last 20 years and he is the co-founder of Five Seasons Ventures, the first European venture fund fully focused on Foodtech.

Ivan Farneti

Founding Partner
Five Season Ventures

Ivan Farneti

Founding Partner
Five Season Ventures

Ivan has been an active venture capital investor for the last 20 years and he is the co-founder of Five Seasons Ventures, the first European venture fund fully focused on Foodtech.

He is passionate about product and technology innovation aimed at solving big challenges in the food industry: from alternative sources of proteins, to functional foods, from new models of food distribution to the reduction of food waste.  At Five Seasons he invested in Tropic Biosciences (plants gene editing), Butternut Box (DNVB pet nutrition), THIS.co (plant-based meat alternatives), Cortilia (D2C fresh food retailer), YFood Labs (balanced meal replacements), Just Spices (D2C spices), Yamo (D2C fresh baby food) and La Fourche (D2C organic groceries).

His experience from previous venture funds in London, includes structuring investments, organizational and strategy development, setting up governance for growth and planning for successful exits. He was an early stage investor in Everbridge, Inc. (Nasdaq: EVBG), Tridion (acq. by SDL Plc), Gomez (acq. by Compuware), among others.

In his spare time he enjoys family life, cooking, fly fishing, and practicing jiu-jitsu with his son Adam.

 

 

 

Karolina Zapadka

Investor
Park Walk Advisors

Karolina Zapadka

Investor
Park Walk Advisors

Karolina Zapadka

Investor
Park Walk Advisors
 

Gentiane Gorlier

General Partner
The Yield Lab

Gentiane Gorlier

General Partner
The Yield Lab

Gentiane Gorlier

General Partner
The Yield Lab
 

Richard Casey

Executive Director
World Small Animal Veterinary Association

Richard Casey

Executive Director
World Small Animal Veterinary Association

Richard Casey

Executive Director
World Small Animal Veterinary Association
 

Ian Wheal

Chief Executive Officer
Breedr

Ian Wheal

Chief Executive Officer
Breedr

Ian Wheal

Chief Executive Officer
Breedr
 

Samuel Laing

Technology Development Officer
Avara Foods

Samuel Laing

Technology Development Officer
Avara Foods

Samuel Laing

Technology Development Officer
Avara Foods
 

Jamie Stein

Co-Founder
Devonian Capital

Jamie Stein

Co-Founder
Devonian Capital

Jamie Stein

Co-Founder
Devonian Capital
 

Marcio Kanas

Executive Director
Nomura Bank

Marcio Kanas

Executive Director
Nomura Bank

Marcio Kanas

Executive Director
Nomura Bank
 

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

 

Jo Malone

Chief Executive Officer
Vet Partners

Jo qualified from Glasgow vet school in 1998, she has been actively involved in both clinical and all business aspects of veterinary life throughout her career. Jo has worked for Minster Vets for the last 16 years focusing on small animal clinical practice.

 

In the last 10 years she has become increasingly involved in managing the practice alongside her clinical role. Being instrumental in growing the practice, improving performance and developing the people within the practice. Jo is passionate about the veterinary profession and the people involved in it.

 

Jo Malone

Chief Executive Officer
Vet Partners

Jo Malone

Chief Executive Officer
Vet Partners

Jo qualified from Glasgow vet school in 1998, she has been actively involved in both clinical and all business aspects of veterinary life throughout her career. Jo has worked for Minster Vets for the last 16 years focusing on small animal clinical practice.

 

In the last 10 years she has become increasingly involved in managing the practice alongside her clinical role. Being instrumental in growing the practice, improving performance and developing the people within the practice. Jo is passionate about the veterinary profession and the people involved in it.

 

In 2015 she became Managing Director of VetPartners and then CEO in 2016.

 

Katrina Hayter

Challenge Director
Innovate UK

Katrina Hayter

Challenge Director
Innovate UK

Katrina Hayter

Challenge Director
Innovate UK
 

Jimmy Barr

Chief Medical Officer
BluePearl Veterinary Hospital

Jimmy Barr

Chief Medical Officer
BluePearl Veterinary Hospital

Jimmy Barr

Chief Medical Officer
BluePearl Veterinary Hospital
 

Edward Chandler

Founding Partner
Fremman Capital

Edward Chandler

Founding Partner
Fremman Capital

Edward Chandler

Founding Partner
Fremman Capital
 

Andre Jordao

Founder and CEO
Barkyn

Andre is an experienced entrepreneur and the CEO of Barkyn, a pet food subscription combining personalised food and telemedicine, growing in multiple European countries.

Andre Jordao

Founder and CEO
Barkyn

Andre Jordao

Founder and CEO
Barkyn

Andre is an experienced entrepreneur and the CEO of Barkyn, a pet food subscription combining personalised food and telemedicine, growing in multiple European countries.

 

Cees Jan Hollander

Global Farming Expertise Manager
Danone

Cees Jan Hollander

Global Farming Expertise Manager
Danone

Cees Jan Hollander

Global Farming Expertise Manager
Danone
 

Julie Fitzpatrick

Scientific Director
Moredun Research Institute

Julie Fitzpatrick

Scientific Director
Moredun Research Institute

Julie Fitzpatrick

Scientific Director
Moredun Research Institute
 

Severine Tasker

Chief Medical Officer
Linnaeus Group

Severine Tasker

Chief Medical Officer
Linnaeus Group

Severine Tasker

Chief Medical Officer
Linnaeus Group
 

Bradley Ringeisen

Executive Director
Innovative Genomics Institute

Bradley Ringeisen

Executive Director
Innovative Genomics Institute

Bradley Ringeisen

Executive Director
Innovative Genomics Institute
 

Scott Holmstrom

Senior Vice President Research and Development
United Animal Health

Scott Holmstrom

Senior Vice President Research and Development
United Animal Health

Scott Holmstrom

Senior Vice President Research and Development
United Animal Health
 

Jon Lowe

Chief Executive Officer
Axiota Animal Health

Jon Lowe

Chief Executive Officer
Axiota Animal Health

Jon Lowe

Chief Executive Officer
Axiota Animal Health
 

Jason Johnson, Phd

President & Global Chief Medical Officer
IDEXX

Jason Johnson, Phd

President & Global Chief Medical Officer
IDEXX

Jason Johnson, Phd

President & Global Chief Medical Officer
IDEXX
 

Julie Lawless

President
Lawless Strategic Communications

Julie Lawless

President
Lawless Strategic Communications

Julie Lawless

President
Lawless Strategic Communications
 

Kate Price

Executive Coach and Organizational Development Consultant
Dr Kate Price Consulting

Kate Price

Executive Coach and Organizational Development Consultant
Dr Kate Price Consulting

Kate Price

Executive Coach and Organizational Development Consultant
Dr Kate Price Consulting
 

Apryle Horbal

President
VetNOW Virtual Care

Apryle Horbal

President
VetNOW Virtual Care

Apryle Horbal

President
VetNOW Virtual Care
 

Isabelle Delannoy

Project Leader
Phibro Animal Health

Isabelle Delannoy

Project Leader
Phibro Animal Health

Isabelle Delannoy

Project Leader
Phibro Animal Health
 

Christie Chavis

Vice President, Animal Nutrition and Health Performance Solutions
DSM

Christie Chavis

Vice President, Animal Nutrition and Health Performance Solutions
DSM

Christie Chavis

Vice President, Animal Nutrition and Health Performance Solutions
DSM
 

Hayden Montgomery

Agriculture Programme Director
Global Methane Hub

Hayden Montgomery

Agriculture Programme Director
Global Methane Hub

Hayden Montgomery

Agriculture Programme Director
Global Methane Hub
 

Laëtitia Gerbe

Partner
Seventure Partners

Laëtitia Gerbe

Partner
Seventure Partners

Laëtitia Gerbe

Partner
Seventure Partners
 

Robert DiMarzo

Principal
DiMarzo Consulting

Robert DiMarzo

Principal
DiMarzo Consulting

Robert DiMarzo

Principal
DiMarzo Consulting
 

Greg Blair

Vice President of Business Development
Zomedica

Greg Blair

Vice President of Business Development
Zomedica

Greg Blair

Vice President of Business Development
Zomedica
 

Charlie Barton

Co-Founder
Virtual Recall

Charlie Barton

Co-Founder
Virtual Recall

Charlie Barton

Co-Founder
Virtual Recall
 

Brian Lindsay

Director
Dairy Sustainability Framework

Brian Lindsay

Director
Dairy Sustainability Framework

Brian Lindsay

Director
Dairy Sustainability Framework
 

Rimma Driscoll

Executive Vice President and Head of Global Strategy, Commercial and Business Development
Zoetis

Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure.

Rimma Driscoll

Executive Vice President and Head of Global Strategy, Commercial and Business Development
Zoetis

Rimma Driscoll

Executive Vice President and Head of Global Strategy, Commercial and Business Development
Zoetis

Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure. She has worked extensively in Pharmaceuticals, Consumer Healthcare and Consumer Products businesses.

 

Sébastien Huron

Chairman of the Executive Board and CEO
Virbac Santé Animale

Sébastien Huron

Chairman of the Executive Board and CEO
Virbac Santé Animale

Sébastien Huron

Chairman of the Executive Board and CEO
Virbac Santé Animale
 

Nuala Summerfield

Co-Founder and Director
Virtual Veterinary Specialists

Nuala Summerfield

Co-Founder and Director
Virtual Veterinary Specialists

Nuala Summerfield

Co-Founder and Director
Virtual Veterinary Specialists
 

Deborah Dullen

President and CEO
BioTraceIT

Deborah Dullen

President and CEO
BioTraceIT

Deborah Dullen

President and CEO
BioTraceIT
 

Catriona Curtis

Group Sustainability and Social Value Manager
Pets at Home

Catriona Curtis

Group Sustainability and Social Value Manager
Pets at Home

Catriona Curtis

Group Sustainability and Social Value Manager
Pets at Home
 

Sven Smit

Chair
McKinsey Global Institute

Sven Smit

Chair
McKinsey Global Institute

Sven Smit

Chair
McKinsey Global Institute
 

Chris Matthews

Business Unit Director UK & Ireland
PHARMAQ Analytiq UK

Chris Matthews

Business Unit Director UK & Ireland
PHARMAQ Analytiq UK

Chris Matthews

Business Unit Director UK & Ireland
PHARMAQ Analytiq UK
 

Nicky Deasy

Investment Committee Member
Biotope by VIB

Nicky Deasy

Investment Committee Member
Biotope by VIB

Nicky Deasy

Investment Committee Member
Biotope by VIB
 

Greg Michel

Investment Partner
Cell Capital

Greg Michel

Investment Partner
Cell Capital

Greg Michel

Investment Partner
Cell Capital
 

Bruce Truman

Founder
BLT Technology & Innovation Group

Bruce Truman

Founder
BLT Technology & Innovation Group

Bruce Truman

Founder
BLT Technology & Innovation Group
 

John Kirkpatrick

Agricultural Manager
Tesco

John Kirkpatrick

Agricultural Manager
Tesco

John Kirkpatrick

Agricultural Manager
Tesco
 

David Hallas

Chief Executive Officer
ECO Animal Health

David Hallas

Chief Executive Officer
ECO Animal Health

David Hallas

Chief Executive Officer
ECO Animal Health
 

Edgar Goluch

Founder and CEO
QSM Diagnostics

Edgar Goluch

Founder and CEO
QSM Diagnostics

Edgar Goluch

Founder and CEO
QSM Diagnostics
 

Dr. Lenore Bacek

Senior Director of Clinical Affairs
BluePearl Veterinary Hospital

Dr. Lenore Bacek

Senior Director of Clinical Affairs
BluePearl Veterinary Hospital

Dr. Lenore Bacek

Senior Director of Clinical Affairs
BluePearl Veterinary Hospital
 

Marie Paul-Lachaud

Referent Animal Health R&D
One Health Pharma

Since 2013, Dr. Marie-Paul Lachaud has served as Head of Program Management Europe at Aratana Therapeutics Inc.. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana’s products, most recently GALLIPRANT.

Since 2009, Dr. Lachaud has also provided services to the veterinary pharmaceutical industry as an experienced independent consultant, with a specific focus on international clinical development and registration of animal drugs.

Marie Paul-Lachaud

Referent Animal Health R&D
One Health Pharma

Marie Paul-Lachaud

Referent Animal Health R&D
One Health Pharma

Since 2013, Dr. Marie-Paul Lachaud has served as Head of Program Management Europe at Aratana Therapeutics Inc.. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana’s products, most recently GALLIPRANT.

Since 2009, Dr. Lachaud has also provided services to the veterinary pharmaceutical industry as an experienced independent consultant, with a specific focus on international clinical development and registration of animal drugs.

From 2000 to 2008, Dr. Lachaud was the European Animal Health Director at ICON Clinical Research in Paris, France. In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and Contract Research Organization dedicated to veterinary drug clinical development and regulatory affairs, which was acquired by ICON in 2000.

Throughout her career, Dr. Lachaud has been involved in transitioning human drugs to meet unmet needs in veterinary medicine. Her work has resulted in significant companion animal health product approvals in Europe and the United-States in a number of innovative therapeutic areas, including reproduction, atopic dermatitis, chronic heart failure, wound healing, chronic kidney disease, acute and chronic pain, obesity, inappetence, cancer, cognitive dysfunction and anxiety-related disorders.

She received her veterinary degree from Alfort National Veterinary School in Paris and her doctorate in veterinary medicine from the University of Paris, France.

 

Marijn Hendrickx

Managing Director
TerraProtein Equity Proteins

Marijn Hendrickx

Managing Director
TerraProtein Equity Proteins

Marijn Hendrickx

Managing Director
TerraProtein Equity Proteins
 

Matthieu Frechin

Chief Executive Officer
Vetoquinol

Matthieu Frechin

Chief Executive Officer
Vetoquinol

Matthieu Frechin

Chief Executive Officer
Vetoquinol
 

Rob Readnour

Managing Director
Mountain Group Capital Partners

Dr. Readnour currently serves on or has visitation rights to the following companies: AgTech Accelerator, a unique startup accelerator focused on discovering and developing emerging agricultural technology companies, Skyline Vet Pharma, a company that is developing veterinary pharmaceuticals using proven delivery technologies to reformulate drugs with established animal health markets, and Boragen, a company that is developing small molecule approaches focused on leveraging the unique chemical properties of boron chemistry, both in crop protection and animal health.

Rob Readnour

Managing Director
Mountain Group Capital Partners

Rob Readnour

Managing Director
Mountain Group Capital Partners

Dr. Readnour currently serves on or has visitation rights to the following companies: AgTech Accelerator, a unique startup accelerator focused on discovering and developing emerging agricultural technology companies, Skyline Vet Pharma, a company that is developing veterinary pharmaceuticals using proven delivery technologies to reformulate drugs with established animal health markets, and Boragen, a company that is developing small molecule approaches focused on leveraging the unique chemical properties of boron chemistry, both in crop protection and animal health.

Prior to joining MGP, Dr. Readnour worked at Elanco Animal Health for 27 years. During his Elanco tenure, he held several senior management positions in which he was responsible for developing and executing Elanco’s Research and Development strategies for entering several new business areas (companion animal pharmaceuticals, vaccines and enzymes). In 2017, these new business areas accounted for nearly 50% of Elanco’s $3.0 billion in sales. Dr. Readnour played an important role in Elanco’s acquisition and integration of Novartis Animal Health, Lohmann Animal Health, ChemGen and Janssen Animal Health. Within Elanco, Dr. Readnour led several initiatives to transform Research and Development through the piloting of new approaches to developing animal health products. He developed and led Elanco’s new technology scouting, acquisition and due diligence efforts. He pioneered a lean product development model which allowed Elanco to enter new areas of business without significant capital investment. He led initial efforts for Elanco to invest in early stage companies and partner with external funding sources to develop products with minimal initial investment from Elanco. Dr. Readnour served as a member of the Food and Agriculture Section of Bio International Board and as an External Advisory Board member for University of Illinois Animal Science Department.
Prior to entering management in Elanco, Dr. Readnour was an internationally recognized expert on animal health product development, analytical chemistry, human food safety and drug residues with 11 publications and 14 external presentations. Throughout his career, Dr. Readnour was responsible for the development and commercialization of 10 animal health products. Dr. Readnour received his PhD in Analytical Chemistry from University of Illinois in 1990.

 

Stephen Lesser

Principal
Novaquest Capital Management

Stephen Lesser

Principal
Novaquest Capital Management

Stephen Lesser

Principal
Novaquest Capital Management
 

Tina Sejersgård Fanø

Executive Vice President, Agriculture & Industrial BioSolutions
Novozymes

Tina Sejersgård Fanø

Executive Vice President, Agriculture & Industrial BioSolutions
Novozymes

Tina Sejersgård Fanø

Executive Vice President, Agriculture & Industrial BioSolutions
Novozymes
 

Rimma Driscoll

Executive Vice President and Head of Global Strategy, Commercial and Business Development
Zoetis

Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure.

Rimma Driscoll

Executive Vice President and Head of Global Strategy, Commercial and Business Development
Zoetis

Rimma Driscoll

Executive Vice President and Head of Global Strategy, Commercial and Business Development
Zoetis

Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure. She has worked extensively in Pharmaceuticals, Consumer Healthcare and Consumer Products businesses.

 

Sébastien Huron

Chairman of the Executive Board and CEO
Virbac Santé Animale

Sébastien Huron

Chairman of the Executive Board and CEO
Virbac Santé Animale

Sébastien Huron

Chairman of the Executive Board and CEO
Virbac Santé Animale
 

Ben North

Director of Portfolio and Innovation Strategy
PHARMAQ

Ben holds the position of Director of Portfolio and Innovation Strategy at PHARMAQ, the aquaculture health business of Zoetis. Ben has worked for PHARMAQ since 2008 and held a variety of technical and commercial roles, including 7 years as the Country Manager of PHARMAQ’s UK business. In 2017 Ben moved across full time to PHARMAQ’s Oslo-based R&D organisation as R&D Portfolio Director, before taking on the current role in 2020, which is focused on delivering an overarching innovation strategy across the continuum of care for aquaculture health.

Ben North

Director of Portfolio and Innovation Strategy
PHARMAQ

Ben North

Director of Portfolio and Innovation Strategy
PHARMAQ

Ben holds the position of Director of Portfolio and Innovation Strategy at PHARMAQ, the aquaculture health business of Zoetis. Ben has worked for PHARMAQ since 2008 and held a variety of technical and commercial roles, including 7 years as the Country Manager of PHARMAQ’s UK business. In 2017 Ben moved across full time to PHARMAQ’s Oslo-based R&D organisation as R&D Portfolio Director, before taking on the current role in 2020, which is focused on delivering an overarching innovation strategy across the continuum of care for aquaculture health.

Before joining PHARMAQ, Ben worked as a post-doctorate researcher at the Stirling University, where he also undertook his PhD. The focus of Ben’s research was investigating the impact of husbandry factors such as stocking density and water quality on fish welfare. This research identified operational welfare indicators for fish in commercial aquaculture systems and generated welfare indices by combining a range of objective indicators. Ben also holds a BSc in Marine Biology, an MSc in Aquaculture and in 2018 completed an Executive MBA program at Warwick Business School.

 

Juan-Carlos Carrillo Peláez

Senior Toxicologist
Shell

Juan-Carlos Carrillo Peláez

Senior Toxicologist
Shell

Juan-Carlos Carrillo Peláez

Senior Toxicologist
Shell
 

Martin Sutcliffe

Aquaculture Specialist
CIEL

Martin Sutcliffe

Aquaculture Specialist
CIEL

Martin Sutcliffe

Aquaculture Specialist
CIEL
 

Adrienne Woodward

Manager of Swine – Specialty Product Research
United Animal Health

Adrienne Woodward

Manager of Swine – Specialty Product Research
United Animal Health

Adrienne Woodward

Manager of Swine – Specialty Product Research
United Animal Health
 

Dr. Kimberly Simmons

Director Global Regulatory Affairs
Clinglobal

Dr. Kimberly Simmons

Director Global Regulatory Affairs
Clinglobal

Dr. Kimberly Simmons

Director Global Regulatory Affairs
Clinglobal
 

Joydeep Kant

Senior Vice President
Syngene

Joydeep Kant

Senior Vice President
Syngene

Joydeep Kant

Senior Vice President
Syngene
 

Udi Cohen

Leader
MSD Animal Health Intelligence Technology Labs

Udi Cohen

Leader
MSD Animal Health Intelligence Technology Labs

Udi Cohen

Leader
MSD Animal Health Intelligence Technology Labs
 

Ian Tarpey

Vice President Biologicals R&D
MSD Animal Health

Ian Tarpey

Vice President Biologicals R&D
MSD Animal Health

Ian Tarpey

Vice President Biologicals R&D
MSD Animal Health
 

Laurie Hueneke

Executive Director, Animal Health Public Policy & Government Relations
MSD Animal Health

Laurie Hueneke

Executive Director, Animal Health Public Policy & Government Relations
MSD Animal Health

Laurie Hueneke

Executive Director, Animal Health Public Policy & Government Relations
MSD Animal Health
 

Alan Beynon

Leader
Poultry Sense

Alan Beynon

Leader
Poultry Sense

Alan Beynon

Leader
Poultry Sense
 

Aaron Schacht

CEO
BIomEdit

Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines.

Aaron Schacht

CEO
BIomEdit

Aaron Schacht

CEO
BIomEdit

Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

 

Chuck Latham

CEO
H&C Animal Health

Chuck Latham

CEO
H&C Animal Health

Chuck Latham

CEO
H&C Animal Health
 

Candise Goodwin

Principal
Outlier Advisors

Candise Goodwin

Principal
Outlier Advisors

Candise Goodwin

Principal
Outlier Advisors

Access the Agenda

The 2023 agenda is here!

Fill out the short form to access a copy immediately. 

View the Agenda to learn more about: 

  1. Our 50+ Industry leading speakers attending the event 
  2. The 20 game changing start-ups who have been selected as our Innovation Showcase finalists 
  3. An audience breakdown of who you can expect to network with in London
  4. A full schedule of sessions including: 
  •    Advancements in Nutritional Solutions and the Future of Feed for Livestock 
  •    Finding a Valuable Strategic Partner: Identifying your Needs to Prioritise the 1,Future of your Business
  •    The Impact of National Climate Commitments on the Animal Health Industry 
  •    And many more!                                                                                

Download the 2023 Agenda

Advisory Board

Author:

Glenn David

EVP and Group President, International Operations, Aquaculture, BioDevices and Pet Insurance
Zoetis Inc.

Glenn David

EVP and Group President, International Operations, Aquaculture, BioDevices and Pet Insurance
Zoetis Inc.

Author:

Robert Kelly

Senior Vice President, Commercial Leader for EURAM Region
MSD

Robert Kelly

Senior Vice President, Commercial Leader for EURAM Region
MSD

Author:

Ellen de Brabander

Executive Vice President R&D and Innovation
Elanco

Ellen de Brabander

Executive Vice President R&D and Innovation
Elanco

Author:

Jean-Luc Michel

Senior Vice President, Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

Jean-Luc Michel

Senior Vice President, Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

Author:

Kathy Turner

Senior Vice President & Global Chief Marketing Officer
IDEXX

Kathy Turner

Senior Vice President & Global Chief Marketing Officer
IDEXX

Author:

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

Author:

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.

Author:

Laurent Genet

Chief Strategy Officer
Nutreco

Laurent Genet joined Nutreco in 2007. He has held a variety of senior management positions in Europe and Asia related to livestock and aquaculture nutrition, health and farming.

Earlier in his career, Laurent worked internationally for the largest French feed producer. He is a Doctor of Veterinary Medicine. Laurent also studied at both the London Business School in the UK, and Affärshögskolan in Norway from which he earned qualifications in business management. 

With a key focus on innovation, Laurent has contributed to Nutreco’s overarching purpose of feeding the future in numerous ways. He spearheaded the company’s first operations in Southeast Asia for both Trouw Nutrition and Skretting, as well as introducing shrimp as a new species for Skretting. Laurent also led the creation of NuFrontiers – Nutreco’s corporate venturing arm. Latterly, he has been heavily involved in identifying and bringing forward new initiatives in the fields of digital technologies, biotechnologies and alternative proteins. With 30 years of experience in animal nutrition, health and farming gained around the world, Laurent has a very clear understanding of the need to be able to look beyond current circumstances in order to prepare for the future.

Laurent Genet

Chief Strategy Officer
Nutreco

Laurent Genet joined Nutreco in 2007. He has held a variety of senior management positions in Europe and Asia related to livestock and aquaculture nutrition, health and farming.

Earlier in his career, Laurent worked internationally for the largest French feed producer. He is a Doctor of Veterinary Medicine. Laurent also studied at both the London Business School in the UK, and Affärshögskolan in Norway from which he earned qualifications in business management. 

With a key focus on innovation, Laurent has contributed to Nutreco’s overarching purpose of feeding the future in numerous ways. He spearheaded the company’s first operations in Southeast Asia for both Trouw Nutrition and Skretting, as well as introducing shrimp as a new species for Skretting. Laurent also led the creation of NuFrontiers – Nutreco’s corporate venturing arm. Latterly, he has been heavily involved in identifying and bringing forward new initiatives in the fields of digital technologies, biotechnologies and alternative proteins. With 30 years of experience in animal nutrition, health and farming gained around the world, Laurent has a very clear understanding of the need to be able to look beyond current circumstances in order to prepare for the future.

Author:

Thomas Zerzan

President Companion Animal
Phibro Animal Health

Thomas Zerzan

President Companion Animal
Phibro Animal Health

Author:

Sébastien Huron

Chairman of the Executive Board and CEO
Virbac Santé Animale

Sébastien Huron

Chairman of the Executive Board and CEO
Virbac Santé Animale

Author:

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Author:

Aaron Schacht

CEO
BIomEdit

Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

Aaron Schacht

CEO
BIomEdit

Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

Selection Committee

Author:

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.

Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.

Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.

Author:

Phil Austin

Founding Partner
Anterra Capital

Phil Austin

Founding Partner
Anterra Capital

Author:

Julia Stephanus

Partner
Borealis Ventures

Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

Julia Stephanus

Partner
Borealis Ventures

Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

Author:

Cindy Cole

Partner
Digitalis Ventures

Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.

Cindy Cole

Partner
Digitalis Ventures

Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.

Author:

Jason Scott

Google and ANIM Fund

Jason Scott

Google and ANIM Fund

Author:

Paul Dick

President
Paul Dick & Associates

Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.

While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.

His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.

Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.

In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).

Paul Dick

President
Paul Dick & Associates

Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.

While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.

His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.

Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.

In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).

Author:

Tom Prins

Head of Dealflow
AquaSpark

Tom manages the process of screening new business opportunities for Aqua-Spark and negotiating new investments. He has been directly involved throughout the investment process for the majority of the current Aqua-Spark portfolio, ranging from investments in feed ingredients, technology, health, genetics and production. Tom joined Aqua-Spark in 2015. Prior to Aqua-Spark, he worked in the Gulf region with the Netherlands Agricultural Attaché for GCC countries and the Netherlands Embassy in the Sultanate of Oman, where he conducted research on the development of local aquaculture industry. He has also spearheaded transnational events to elevate public and private dialogue on emerging opportunities in aquaculture. Tom received a Master in Business Geography from Utrecht University. A fervent surfer, Tom is dedicated to conserving the ocean for future generations.    

Tom Prins

Head of Dealflow
AquaSpark

Tom manages the process of screening new business opportunities for Aqua-Spark and negotiating new investments. He has been directly involved throughout the investment process for the majority of the current Aqua-Spark portfolio, ranging from investments in feed ingredients, technology, health, genetics and production. Tom joined Aqua-Spark in 2015. Prior to Aqua-Spark, he worked in the Gulf region with the Netherlands Agricultural Attaché for GCC countries and the Netherlands Embassy in the Sultanate of Oman, where he conducted research on the development of local aquaculture industry. He has also spearheaded transnational events to elevate public and private dialogue on emerging opportunities in aquaculture. Tom received a Master in Business Geography from Utrecht University. A fervent surfer, Tom is dedicated to conserving the ocean for future generations.    

Author:

Karolina Zapadka

Investor
Park Walk Advisors

Karolina Zapadka

Investor
Park Walk Advisors

Author:

Gentiane Gorlier

General Partner
The Yield Lab

Gentiane Gorlier

General Partner
The Yield Lab

Author:

Jamie Stein

Co-Founder
Devonian Capital

Jamie Stein

Co-Founder
Devonian Capital

Author:

John McNicol

Founder and Director
Kelvin Capital

John McNicol

Founder and Director
Kelvin Capital

2023 Partners

Animal Health Innovation Europe is supported by the most influential bodies across the Animal Health, Nutrition and Veterinary industries.

Be one of them, communicate about the event to your network, spread the word and become a Supporter of the Animal Health, Nutrition and Technology Innovation series.

Headline Partner

Platinum Associate Partners

Associate Partners

Start-up Development Partner

Knowledge Partner

Consulting Partner

Senior Event Partner

Event Partner

Become a partner

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920, email Stephen Swarray at [email protected], Harrison Sharp at [email protected] or downloading our agenda and clicking the "Interested in Sponsorship" box.

Press Partnerships

Whether you are an association, embassy, industry body or publication, we can offer a tailored marketing partnership to suit your needs. As a Media Partner we can:

  • Promote your organisation as an event partner across all conference materials, including the website, brochure, emails and on-site programme
  • Offer your members or readers a discount on their registration fee for Animal Health Investment Europe
  • Provide one free press pass to attend
  • Distribute promotional materials at the conference

If you are a registered industry journalist or member of the press and would like to arrange an interview with a speaker or to discuss the event please contact:

Sarah Rowlands
Marketing Director
E: sarah.rowlands@kisacoresearch.com

Photo Gallery

View photos of Animal Health, Nutrition and Technology Innovation events over the years! View the full photo gallery here. 

Venue

155 Bishopsgate, London EC2M 3YD

Join us in 2023 at etc. venues, 155 Bishopsgate, London EC2M 3YD

Find nearby hotels here: https://HotelMap.com/MKZ5V

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket price will increase in

Saturday, January 28, 2023 to Wednesday, March 8, 2023
Emerging
£1,399
Academics
Start-ups & Emerging
Charities
Angel and Venture Capital Investors
Please note: Service providers do not qualify for this rate
Saturday, January 28, 2023 to Wednesday, March 8, 2023
Delegate
£2,699
Pharmaceutical Companies
Animal Health Companies
To increase your brand presence, contact Stephen: [email protected]
Saturday, December 3, 2022 to Thursday, March 9, 2023
Multinationals & Service Providers
£3,499
CROs & CMOs
Multinationals
M&A Advisors
Private Equity
Service Providers
Incubators & Accelerators
Companies with over $100m annual turnover
To increase your brand presence, contact Stephen: [email protected]
Preparing registration...
Payment Terms for Animal Health, Nutrition and Technology Innovation Europe:
  • Please note that a £49 processing fee will apply to any invoices requested.
  • Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
  • All Prices are in GBP
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined.
  • Please view our Cancellation Policy.
  • Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
  • Please Note: No additional discounts are available on ‘Emerging Company’ pricing.

Resources

Download Resource

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us